Shots:
- The US FDA has approved neffy 1mg (epinephrine nasal spray) to treat type I allergic reactions (incl. anaphylaxis) in children [≥4yrs. & 15-30kg (33-66lbs)]; commercially available in the US by end of May’25
- Approval was based on extensive clinical data with PK/PD results comparable to approved epinephrine injections in both pediatric & adult pts. Human factor studies showed that 10yr. old children along with untrained individuals can effectively administer neffy by following instructions
- Neffy nasal spray provides needle-free & easy-to-use approach for the treatment of severe allergies with 24mos. shelf life at room temperature & tolerance up to 122°F (50°C) for ~3mos.
Ref: Globenewswire | Image: ARS Pharmaceuticals
Related News:- ARS Pharmaceuticals Reports the EC’s Approval of Eurneffy (Adrenaline Nasal Spray) to Treat Type I Allergic Reactions
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
